Analysts Upgrade/Downgrade Activity of Acorda Therapeutics, Inc. (ACOR)

coca-cola financial report

Acorda Therapeutics, Inc. (ACOR) belonging to the Medical sector has surged 1.78% and closed its last trading session at $17.2.

Currently, the stock has a 1 Year Price Target of $27.86.

The consensus recommendation, according to Zacks Investment research, is 2.25. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

The Stock had a 2.25 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.14 and 1.86 respectively.

Acorda Therapeutics, Inc. reported its EPS as $0.07 with the analysts projecting the EPS of the stock as $0.2. The company beat the analyst EPS Estimate with the difference of $-0.13. This shows a surprise factor of -0.65%.

Many analysts have provided their estimated foresights on Acorda Therapeutics, Inc. Earnings, with 7 analysts believing the company would generate an Average Estimate of $0.49.

Whereas they predicted High and Low Earnings Estimate as $0.77 and $0.37 respectively. While in the same Quarter Previous year, the Actual EPS was $0.07.

Analysts are also projecting an Average Revenue Estimate for Acorda Therapeutics, Inc. as $140910 in the Current Quarter. This estimate is provided by 7 analysts.

The High Revenue estimate is predicted as 145480, while the Low Revenue Estimate prediction stands at 136700. The company’s last year sales total was 127460.

For the Current Quarter, the growth estimate for Acorda Therapeutics, Inc. is 600%, while for the Next Quarter the stock growth estimate is 1875%.

In the past 5 years, the stock showed growth of 3.31% per annum. While for the next 5 years, the growth estimate is 29%.

Insider Trades for Acorda Therapeutics, Inc. show that the latest trade was made on 14 May 2017 where Hindman (Andrew Asa), the Officer completed a transaction type “Sell” in which 7704 shares were traded at a price of $15.75.

Acorda Therapeutics, Inc. (ACOR) has the market capitalization of $787.9 Million. The company rocked its 52-Week High of $33 and touched its 52-Week Low of $13.6.

The stock has Return on Assets (ROA) of -4 percent. Return on Equity (ROE) stands at -7.9% and Return on Investment (ROI) of -3 percent.

The stock is currently showing YTD performance of -8.51 Percent. The company has Beta Value of 1.7 and ATR value of 0.74. The Weekly and Monthly Volatility stands at 7.48% and 4.73%.